LMAT:NSD-LeMaitre Vascular Inc. (USD)

EQUITY | Medical Instruments & Supplies | NASDAQ Global Market

Last Closing

USD 92.89

Change

+1.18 (+1.29)%

Market Cap

USD 0.44B

Volume

0.14M

Analyst Target

USD 34.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

LeMaitre Vascular Inc provides medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

+12.09 (+2.52%)

USD 170.28B
COO The Cooper Companies, Inc. Com..

+0.56 (+0.51%)

USD 21.88B
ALGN Align Technology Inc

-0.49 (-0.19%)

USD 19.00B
HOLX Hologic Inc

+0.64 (+0.79%)

USD 18.77B
RGEN Repligen Corporation

+2.89 (+1.98%)

USD 8.24B
MMSI Merit Medical Systems Inc

+1.15 (+1.18%)

USD 5.69B
XRAY Dentsply Sirona Inc

+0.01 (+0.04%)

USD 5.48B
ICUI ICU Medical Inc

+7.75 (+4.44%)

USD 4.26B
AZTA Azenta Inc

-0.94 (-1.90%)

USD 2.42B
STAA STAAR Surgical Company

-0.08 (-0.21%)

USD 1.83B

ETFs Containing LMAT

VDGR:AU Vanguard Diversified Grow.. 0.41 % 0.00 %

-0.06 (-0.21%)

USD 0.79B
VDHG:AU Vanguard Diversified High.. 0.40 % 0.00 %

-0.14 (-0.21%)

USD 2.46B
VDBA:AU Vanguard Diversified Bala.. 0.38 % 0.00 %

+0.01 (+-0.21%)

USD 0.65B
VDCO:AU Vanguard Diversified Cons.. 0.31 % 0.00 %

+0.05 (+-0.21%)

USD 0.21B
EWO iShares MSCI Austria ETF 0.00 % 0.47 %

+0.06 (+-0.21%)

N/A
RNSC First Trust Small Cap US .. 0.00 % 0.60 %

+0.12 (+-0.21%)

USD 0.03B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 63.65% 89% A- 92% A
Dividend Return 1.13% 38% F 27% F
Total Return 64.78% 89% A- 92% A
Trailing 12 Months  
Capital Gain 68.40% 87% B+ 89% A-
Dividend Return 1.41% 38% F 20% F
Total Return 69.82% 87% B+ 89% A-
Trailing 5 Years  
Capital Gain 192.02% 90% A- 90% A-
Dividend Return 8.19% 88% B+ 27% F
Total Return 200.20% 90% A- 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 26.74% N/A N/A 82% B
Dividend Return 27.84% N/A N/A 82% B
Total Return 1.11% N/A N/A 27% F
Risk Return Profile  
Volatility (Standard Deviation) 37.02% N/A N/A 50% F
Risk Adjusted Return 75.21% N/A N/A 90% A-
Market Capitalization 0.44B 75% C 80% B-

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 44.40 31% 20%
Price/Book Ratio 6.45 14% 18%
Price / Cash Flow Ratio 56.07 17% 5%
Price/Free Cash Flow Ratio 34.18 15% 10%
Management Effectiveness  
Return on Equity 12.49% 91% 82%
Return on Invested Capital 9.79% 82% 78%
Return on Assets 8.27% 91% 93%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.